Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- OBJECT label "Aminopeptidase N activity in a dose-and time-dependent manner" provenance.
- OBJECT label "Aminopeptidase N activity in a dose-and time-dependent manner" provenance.
- OBJECT label "Aminopeptidase N activity in a dose-and time-dependent manner" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "with usual care in patients not requiring oxygen supplementation , leading to a NNH value of 26.7 ( 95%CI 18.1–50.9 , p < 0.05 )" provenance.
- OBJECT label "both tumor necrosis factor" provenance.
- OBJECT label "both tumor necrosis factor" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "to be an effective treatment in the subgroup of patients requiring oxygen supplementation" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to reduce maternal mortality, can" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "to severe side effects" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "encouraging resultswhile vaccines are currently being evaluated in phase III trials" provenance.
- OBJECT label "more frequently" provenance.
- OBJECT label "more frequently" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.
- OBJECT label "the number of ventilator-free days among patients with COVID-19-associated ARDS" provenance.